KDC-MN-260 – Kodiac biolabs

Plain-language summaryIntrigue 55 / 100

Yohimbine is an alkaloid extracted from the bark of an African tree (Pausinystalia johimbe), used historically as an aphrodisiac. Pharmacologically it is an alpha-2 receptor blocker, which means it does the opposite of clonidine: it ramps up the sympathetic nervous system, raising noradrenaline release. At low doses it can produce alertness, anxiety, and a small erectile-function benefit; at higher doses it triggers panic-like states and is used in research as a deliberate panic challenge. Sold widely as a fat-loss and pre-workout supplement, with mixed clinical evidence. The pressor and anxiogenic effects make it dangerous for people with cardiovascular disease or anxiety disorders. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

41/100

The canonical alpha-2 pharmacological probe; low novelty but durable bench utility for noradrenergic research programs

Look, yohimbine isn’t a compound you discover. It’s one you already know. The alpha-2 adrenergic antagonist literature is old enough to be cited in textbooks that are themselves dated, and yohimbine sits at the center of that literature as the reference standard. That’s both its greatest asset and the reason its overall research merit sits in the low 40s.

The mechanism is textbook. Presynaptic autoinhibition blockade, increased noradrenergic outflow, downstream cascade of blood pressure elevation, anxiety, tachycardia, mydriasis. Nobody is writing a grant to characterize the mechanism of yohimbine. The pharmacology has been settled for decades. What keeps it alive is the same thing that keeps ketamine alive after decades of use: sometimes you need the probe more than you need the novelty.

Where yohimbine earns its keep is the panic disorder provocation paradigm. Charney’s group at Yale, and multiple independent replications, have used IV yohimbine challenges to map noradrenergic dysregulation in PTSD, panic disorder, and stress-sensitization models. The selectivity profile is clean, roughly 50-fold alpha-2 over alpha-1 (Ki approximately 1 to 5 nM versus alpha-1), and the short plasma half-life of around 0.6 hours gives investigators temporal control that a longer-acting compound would undermine. That’s genuine bench-to-clinic utility. It doesnt generate new biology, but it lets you interrogate existing biology with real precision.

The therapeutic end is considerably weaker. The erectile dysfunction angle, which accounts for most of its commercial footprint, has an evidence base that consistently underdelivers. Multiple controlled trials show inconsistent effects and modest effect sizes that wouldn’t satisfy a high-standard systematic review. The secondary 5-HT1A partial agonism at around 100 nM adds theoretical texture but doesn’t meaningfully shift the clinical picture.

What we like: the compound is well-characterized, dosing windows and washout periods are firmly established across decades of human pharmacology studies, and purity from pharmaceutical-grade suppliers is reliable. If your lab is running any kind of noradrenergic activation study or a sympathetic challenge protocol, yohimbine is still the tool you reach for. thats not nothing.

What we don’t like: there is essentially nothing new here. No serious group is exploring genuinely novel indications, the mechanism space is fully occupied, and sourcing from OTC channels introduces purity variance that can undermine experimental control. For investigators specifically working on noradrenergic circuits or panic neurobiology, yohimbine is necessary. For everyone else, it’s a reference standard worth knowing and not much more.

Novelty: 20
Mechanism promise: 28
In-category differentiation: 42
Evidence quality: 58
Translational signal: 48
Research bench value: 68

Rationale Yohimbine scores low on novelty and mechanism freshness because the alpha-2 antagonism story is textbook-settled, but its bench value lifts the overall via genuine indispensability in noradrenergic and panic-biology provocation paradigms. No scheduling or category cap applies; the 41 reflects a compound that earns its place as a probe, not as a discovery target.

Selective alpha-2 adrenergic antagonist

An indole alkaloid alpha-2 adrenergic antagonist from Pausinystalia johimbe; the canonical pharmacological probe for noradrenergic activation.

Abstract

Yohimbine (17-alpha-hydroxy-yohimban-16-alpha-carboxylic acid methyl ester; CAS 146-48-5; molecular formula C21H26N2O3; molecular weight 354.45) is an indole alkaloid isolated from the bark of Pausinystalia johimbe (Rubiaceae) and from Rauwolfia species. The compound is a selective alpha-2 adrenergic antagonist (Ki approximately 1 to 5 nM) with secondary 5-HT1A partial agonism (Ki approximately 100 nM); selectivity for alpha-2 over alpha-1 is approximately 50-fold. Pharmacologically, yohimbine increases central noradrenergic outflow by blocking presynaptic autoinhibition, producing anxiety, increased blood pressure, mydriasis, and tachycardia. Used in clinical research as a provocation test for panic disorder (where vulnerability to alpha-2 antagonism predicts panic susceptibility) and as a positive control in studies of noradrenergic regulation. Folk use as an aphrodisiac for erectile dysfunction has limited supporting evidence. Plasma half-life is approximately 0.6 hours. Used as the canonical alpha-2 antagonist in academic pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-260Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-260

Yohimbine

Abstract

Read the full monograph